Document Detail

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients.
MedLine Citation:
PMID:  23300029     Owner:  NLM     Status:  Publisher    
There are many active drugs to treat metastatic renal cell carcinoma (mRCC) patients who progress through their first-line vascular endothelial growth factor (VEGF) inhibitor. Many clinicians choose a second-line VEGF inhibitor based on the type of response to first-line VEGF inhibitor, without data supporting this practice. This study was conducted to determine the association of response to second-line VEGF inhibitor with response to first-line VEGF inhibitor. All mRCC patients in participating centers of the International mRCC Database Consortium who were treated from January 2004 through June 2011 with a second-line VEGF inhibitor after failure of a different first-line VEGF inhibitor were retrospectively identified. The primary outcome is objective response rate (ORR) and the secondary outcome is progression-free survival (PFS) in each line of therapy. Of 1,602 total database patients, 464 patients received a first- and second-line VEGF inhibitor. The ORR to first-line therapy was 22 %, and the ORR to second-line therapy was 11 %. The ORR to second-line therapy was not different among patients achieving partial response versus stable disease versus progressive disease to first-line therapy (14 % vs. 10 % vs. 11 %, respectively; chi-squared trend test p = 0.17). The median PFS on first-line VEGF-targeted therapy was 7.5 months (95 % CI, 6.6-8.1), and the median PFS on second-line VEGF inhibitor was 3.9 months (95 % CI, 3.6-4.5). There was no correlation between first-line and second-line PFS (Pearson correlation coefficient 0.025; p = 0.59). The clinical response to a second-line VEGF inhibitor is not dependent on response to the first-line VEGF-inhibitor. Further studies are needed to define clinical parameters that predict response to second-line therapy to optimize the sequence of VEGF-targeted therapy in metastatic RCC patients.
Mhd Y Al-Marrawi; Brian I Rini; Lauren C Harshman; Georg Bjarnason; Lori Wood; Ulka Vaishampayan; Mary Mackenzie; Jennifer J Knox; Neeraj Agarwal; Hulayel Al-Harbi; Christian Kollmannsberger; Min-Han Tan; Sun Young Rha; Frede N Donskov; Scott North; Toni K Choueiri; Daniel Y Heng;
Related Documents :
16184589 - Hypereosinophilic syndrome: an update.
23804139 - P53 expression in pretreatment specimen predicts response to neoadjuvant chemotherapy i...
23286739 - Retrospective evaluation of doxorubicin-piroxicam combination for the treatment of tran...
16551519 - Optimizing chemotherapy and targeted agent combinations in nsclc.
23357879 - Wild-type kras and braf could predict response to cetuximab in chinese colorectal cance...
23912599 - Impact of boost irradiation on pelvic lymph node control in patients with cervical cancer.
7608719 - Prospective evaluation of a prognostic index for intrinsic supratentorial tumours.
21108439 - Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in ch...
22500049 - Advancing the status of mpn pathogenesis.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-9
Journal Detail:
Title:  Targeted oncology     Volume:  -     ISSN:  1776-260X     ISO Abbreviation:  Target Oncol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101270595     Medline TA:  Target Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  EGFR-directed monoclonal antibodies in non-small cell lung cancer.
Next Document:  The design and analysis of parallel experiments to produce structurally identifiable models.